Resultados da pesquisa - Alexander E. Perl

Refinar resultados
  1. 1
    The role of targeted therapy in the management of patients with AML

    The role of targeted therapy in the management of patients with AML Por Alexander E. Perl

    Publicado em 2017
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    Availability of FLT3 inhibitors: how do we use them?

    Availability of FLT3 inhibitors: how do we use them? Por Alexander E. Perl

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    The role of targeted therapy in the management of patients with AML

    The role of targeted therapy in the management of patients with AML Por Alexander E. Perl

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  4. 4
    Gilteritinib: potent targeting of FLT3 mutations in AML

    Gilteritinib: potent targeting of FLT3 mutations in AML Por Mark J. Levis, Alexander E. Perl

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  5. 5
    Advances in patient care through increasingly individualized therapy

    Advances in patient care through increasingly individualized therapy Por Courtney D. DiNardo, Alexander E. Perl

    Publicado em 2019
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  6. 6
    Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy

    Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemothera... Por Alexander E. Perl, Margaret Kasner, Doris Shank, Selina M. Luger, Martin Carroll

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia

    Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia Por Pamela J. Sung, Mayumi Sugita, Holly K. Koblish, Alexander E. Perl, Martin Carroll

    Publicado em 2019
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib Por Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations Por Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith

    Publicado em 2020
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study Por Alexander E. Perl, Naval Daver, Keith W. Pratz, Joseph Maly, Wan‐Jen Hong, Erkut Bahceci, Bo Tong, Tian Tian, Kimberley Dilley

    Publicado em 2019
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome Por Ivana Gojo, Alexander E. Perl, Selina M. Luger, Maria R. Baer, Kelly J. Norsworthy, Kenneth S. Bauer, Michael Tidwell, Stephanie Fleckinger, Martin Carroll, Edward A. Sausville

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia

    Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia Por Christine M. McMahon, Jonathan Canaani, Bryan Rea, Rachel L. Sargent, Julianne Qualtieri, Christopher D. Watt, Jennifer J.D. Morrissette, Martin Carroll, Alexander E. Perl

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    Harnessing the benefits of available targeted therapies in acute myeloid leukaemia

    Harnessing the benefits of available targeted therapies in acute myeloid leukaemia Por Hagop M. Kantarjian, Nicholas J. Short, Courtney D. DiNardo, Eytan M. Stein, Naval Daver, Alexander E. Perl, Eunice S. Wang, Andrew H. Wei, Martin S. Tallman

    Publicado em 2021
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  14. 14
    A robust xenotransplantation model for acute myeloid leukemia

    A robust xenotransplantation model for acute myeloid leukemia Por P V Sanchez, Robin Perry, Jean‐Emmanuel Sarry, Alexander E. Perl, Kathleen M. Murphy, Cezary Swider, Adam Bagg, John Choi, Jaclyn A. Biegel, Gwenn Danet-Desnoyers, Martin Carroll

    Publicado em 2009
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

    Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML Por Jorge E. Cortés, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis

    Publicado em 2018
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  16. 16
    A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220

    A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220 Por Panpan Hou, Chao Wu, Yuchen Wang, Rui Qi, Dheeraj Bhavanasi, Zhixiang Zuo, Cédric Dos Santos, Shuliang Chen, Yu Chen, Hong Zheng, Hong Wang, Alexander E. Perl, Deyin Guo, Jian Huang

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations Por Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason E. Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller

    Publicado em 2018
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL

    Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL Por Christian Hurtz, Gerald Wertheim, Joseph P. Loftus, Daniel Blumenthal, Anne W. Lehman, Yong Li, Asen Bagashev, Bryan Manning, Katherine D. Cummins, Janis K. Burkhardt, Alexander E. Perl, Martin Carroll, Sarah K. Tasian

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML Por Amy Sexauer, Alexander E. Perl, Xiaochuan Yang, Michael J. Borowitz, Christopher D. Gocke, Trivikram Rajkhowa, Christian Thiede, Mark G. Frattini, Grant E. Nybakken, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Mark J. Levis

    Publicado em 2012
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Por Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, José C. Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci

    Publicado em 2018
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: